Decoy Therapeutics Reports Increased Losses and First Grant Revenue in Q2 2026

Decoy Therapeutics Inc. reported its financial results for the second quarter of 2026, revealing a net loss of $2.37 million, a significant increase from the $957,825 loss recorded in the same period of 2025. For the first half of 2026, the company reported a net loss of $4.60 million, compared to a loss of $2.67 million in the first half of the previous year. The increase in losses is attributed to higher operating expenses, particularly in research and development, which surged to $1.30 million in the second quarter, up from $116,383 in the prior year. Total operating expenses for the first half of 2026 reached $4.91 million, compared to $2.68 million in the same period of 2025.

The company generated grant revenue of $227,629 in the second quarter of 2026, marking its first revenue since the merger with Legacy Decoy in November 2025. This revenue was derived from a grant from the Gates Foundation, reflecting an increase in allowable expenses under the grant. The total cash, cash equivalents, and restricted cash as of June 30, 2026, stood at $8.29 million, a decrease from $10.71 million at the end of 2025, primarily due to cash used in operating activities. The company’s working capital was reported at $3.8 million.

Decoy Therapeutics has undergone significant strategic changes following its merger with Legacy Decoy, which has expanded its operational capabilities and product pipeline. The company is focused on advancing its proprietary IMP3ACT platform, which aims to develop peptide conjugate therapeutics targeting infectious diseases and oncology. The merger has also led to the integration of additional assets, including two small molecule drugs, SP-3164 and seclidemstat, which are in various stages of development. The company plans to file an Investigational New Drug (IND) application with the FDA or the European equivalent in the first half of 2027.

In terms of operational metrics, Decoy Therapeutics has not yet commercialized any products and continues to rely on grant funding to support its research initiatives. The company’s employee headcount remains stable, and it is actively seeking additional funding sources to support its ongoing operations and product development. The recent private placement, which raised approximately $3.5 million, is expected to provide necessary capital for advancing clinical trials and other corporate purposes.

Looking ahead, Decoy Therapeutics acknowledges the challenges of maintaining sufficient financial resources to support its operations. The company has expressed the need to raise additional capital to continue its development efforts and has indicated that failure to secure funding could adversely affect its business and financial condition. The management remains optimistic about the potential of its product candidates and the strategic direction following the merger, aiming to leverage its enhanced capabilities to address unmet medical needs in the biotechnology sector.